Savara shares surge 17.35% after hours on FDA designations, positive trials, and $224.5M in financing.

Savara Inc. surged 17.35% in after-hours trading, driven by multiple positive catalysts. The stock’s rise aligns with FDA designations, positive trial results for its lead candidate MOLBREEVI, and a $149.5M public offering that strengthened its balance sheet. Oppenheimer raised its price target to $9, citing MOLBREEVI’s potential in treating autoimmune PAP, while a $75M royalty funding agreement further supports commercialization. Savara also announced pivotal steps toward BLA resubmission and proactive investor engagement, bolstering market confidence. Institutional buying and analyst upgrades, including a $11 price target from Guggenheim, amplified momentum. The stock’s 52-week high and overbought technical indicators underscore investor optimism ahead of its participation in key healthcare conferences.